72
Participants
Start Date
May 31, 2010
Primary Completion Date
December 31, 2010
BI 660848
2 mg oral drinking solution
BI 660848
10 mg oral drinking solution
BI 660848
20 mg oral drinking solution
BI 660848
50 mg oral drinking solution
BI 660848
100 mg oral drinking solution
BI 660848
150 mg oral drinking solution
BI 660848
200 mg oral drinking solution
BI 660848
400 mg oral drinking solution
BI 660848
600 mg oral drinking solution
BI 660848
10,0 mg immediate release tablet
BI 660848
50,0 mg immediate release tablet
Placebo
matching placebo (oral drinking solution and IR tablets)
1284.1.1 Boehringer Ingelheim Investigational Site, Ingelheim
Lead Sponsor
Boehringer Ingelheim
INDUSTRY